FINNENCE ▪ THE WIRE FILE
THE WIRE · № 78712
SEC Filing■ Unclear/unknown
PLTR filed 4 on 2026-10-13
KINDSEC Filing
DIRECTION■ Unclear/unknown
SOURCES2
ENTITIES1
STORY SIZESTANDALONE
FIRST SEEN
LAST UPDATE
STATEactive
01 THE MACHINE READ
WHY IT MATTERS.
A Form 4 reveals insider activity, but without buy/sell detail the market signal is indeterminate.
Routine insider filing, direction unspecified
CATALYST TO WATCH
Transaction type and size in the filing
MAIN RISK
May reflect insider selling if a disposal
FULL DISPATCH
PLTR (CIK 0001823923) filed a 4 on 2026-10-13.
02 THE STORY SO FAR
THE RECORD, IN ORDER.
STANDALONE ITEM — NOT YET FOLDED INTO A DEVELOPING STORY.
03 WHO'S INVOLVED
ENTITIES ON FILE.
SUBJECTPalantir · PLTR
04 RECEIPTS
THE SOURCE RECORD.
2 SOURCES CONFIRMED05 PROPAGATION
WHAT THIS TOUCHES.
→INFERENCEfilings generate company commentary
New Phase 3 trial: A Study on the Impact of Recombinant Zoster Vaccine on Major Adverse Cardiovascular Events in Adults >=50 Years of Age With Established Cardiovascular Disease or With >=2 Cardiovascular Risk Factors — GlaxoSmithKline2026-10-13 12:00 UTC
New Phase 3 trial: A Study on the Impact of Recombinant Zoster Vaccine on Major Adverse Cardiovascular Events in Adults >=50 Years of Age With Established Cardiovascular Disease or With >=2 Cardiovascular Risk Factors — GlaxoSmithKline2026-10-13 12:00 UTC
→INFERENCEfilings generate company commentary
New Phase 3 trial: Phase III Trial of VDJ001 In Patients With Idiopathic Multicentric Castleman Disease — Beijing VDJBio Co., LTD.2026-10-13 12:00 UTC
New Phase 3 trial: Phase III Trial of VDJ001 In Patients With Idiopathic Multicentric Castleman Disease — Beijing VDJBio Co., LTD.2026-10-13 12:00 UTC
→INFERENCEfilings generate company commentary
New Phase 3 trial: BL-M07D1 (Trastuzumab Brengitecan T-bren) vs Standard of Care Platinum-based Chemotherapy (PBC) for HER2-expressing Metastatic Urothelial Cancer After Progression on Anti-PD-(L)1-based Therapy — SystImmune Inc.2026-10-13 12:00 UTC
New Phase 3 trial: BL-M07D1 (Trastuzumab Brengitecan T-bren) vs Standard of Care Platinum-based Chemotherapy (PBC) for HER2-expressing Metastatic Urothelial Cancer After Progression on Anti-PD-(L)1-based Therapy — SystImmune Inc.2026-10-13 12:00 UTC
→INFERENCEfilings generate company commentary
New Phase 3 trial: A Study of Zasocitinib in Adults With Psoriatic Arthritis (LATITUDE PsA NeXt) — Takeda2026-10-13 12:00 UTC
New Phase 3 trial: A Study of Zasocitinib in Adults With Psoriatic Arthritis (LATITUDE PsA NeXt) — Takeda2026-10-13 12:00 UTC
→INFERENCEfilings generate company commentary
New Phase 3 trial: Efficacy and Safety of Combination Therapy Compared With Monotherapy in Patients With Benign Prostatic Hyperplasia — Il-Yang Pharm. Co., Ltd.2026-10-13 12:00 UTC
New Phase 3 trial: Efficacy and Safety of Combination Therapy Compared With Monotherapy in Patients With Benign Prostatic Hyperplasia — Il-Yang Pharm. Co., Ltd.2026-10-13 12:00 UTC
→INFERENCEfilings generate company commentary
New Phase 3 trial: To Evaluate HU-045 With Moderate to Severe Glabellar Lines — Huons Biopharma2026-10-13 12:00 UTC
New Phase 3 trial: To Evaluate HU-045 With Moderate to Severe Glabellar Lines — Huons Biopharma2026-10-13 12:00 UTC
KEEP READING THE MACHINE
Summaries are generated and may contain errors — every claim links its sources.